The first head-to-head comparison of an IL-17 inhibitor and TNF inhibitor in moderate to severe psoriatic arthritis has shown ixekizumab superior to adalimumab for simultaneous improvement of joint and skin disease. The open-label, blinded assessor study of 566 patients through to 24 weeks of treatment found 36% of patients treated with ixekizumab and 28% of ...
Ixekizumab pips adalimumab on combined PsA end point
By Mardi Chapman
9 Oct 2019